Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Hepatocellular 7Carcinoma, Non-Small-Cell Lung 3Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Turcot syndrome 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Melanoma 1Lung Neoplasms 1Lung Diseases 1Hemangiosarcoma 1Colorectal Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

Paclitaxel 6Radiotherapy 5Carboplatin 5capmatinib 2Radiosurgery 2Gemcitabine 2tetrathiomolybdate 1spartalizumab 1pembrolizumab 1palbociclib 1onartuzumab 1nintedanib 1fludarabine phosphate 1fludarabine 1efaproxiral 1durvalumab 1binimetinib 1aldesleukin 1Vinorelbine 1Technetium Tc 99m Sestamibi 1Taxes 1Sorafenib 1Platinum 1Nivolumab 1Neoadjuvant Therapy 1Magnetic Resonance Spectroscopy 1Interleukin-2 1Immunotherapy 1Immunoenzyme Techniques 1Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Adenocarcinoma of Lung × spartalizumab × Clear all
NCT02466568 2019-09-09

Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Withdrawn
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡